t, for the treatment of malignant pleural mesothelioma; and Erbitux, indicated both as a single agent and with another chemotherapy agent for the treatment of certain types of colorectal cancers, and as a single agent or in combination with radiation therapy for the treatment of certain types of head and neck cancers. The company’s oncology products also comprise Cyramza, for the treatment of various cancers, with approvals comprising approved in 2014 in the U.S. and the European Union (EU), and in Japan in 2015, both as a single agent and in combination with another agent as a second-line treatment of advanced or metastatic gastric cancer; approved in 2014 in the U.S., and in the EU in 2016, in combination with another agent as a second-line treatment of metastatic NSCLC; and approved in 2015 in the U.S., and in the EU in 2016, as a second-line treatment of metastatic colorectal cancer. In addition, the company’s oncology products include Gemzar, for the treatment of pancreatic cancer; in combination with other agents, for the treatment of metastatic breast cancer, NSCLC, and advanced or recurrent ovarian cancer; and in the EU for the treatment of bladder cancer; and Portrazza, approved in 2015 in the U.S. for use in combination with other agents as a first-line treatment of metastatic squamous NSCLC, and approved in 2016 in the EU for use in combination with other agents as a first-line treatment for epidermal growth factor receptor expressing squamous NSCLC Cardiovascular Products The company’s cardiovascular products include Cialis, for the treatment of erectile dysfunction and benign prostatic hyperplasia; Effient, for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are managed with an artery-opening procedure known as percutaneous coronary intervention (PCI), including patients undergoing angioplasty, atherectomy, or stent placement; and ReoPro, for use as an adjunct to PCI for the prevention of cardiac ischemic complications. Animal Health Products segment This segment’s products for food animals include Rumensin, a cattle feed additive that improves feed efficiency and growth and also controls and prevents coccidiosis; Posilac, a protein supplement to improve milk productivity in dairy cows; Paylean and Optaflexx, leanness and performance enhancers for swine and cattle, respectively; Tylan, an antibiotic used to control certain diseases in cattle, swine, and poultry; Micotil, Pulmotil, and Pulmotil AC, antibiotics used to treat respiratory disease in cattle, swine, and poultry, respectively; Coban, Monteban, and Maxiban, anticoccidial agents for use in poultry; Surmax (sold as Maxus in some countries), a performance improver for swine and poultry; and Imrestor, a biopharmaceutical that restores neutrophil function in peri-parturient dairy cows. The company’s products for companion animals include Trifexis, a monthly chewable tablet for dogs that kills fleas, prevents flea infestations, prevents heartworm disease, and controls intestinal parasite infections; Comfortis, a chewable tablet that kills fleas and prevents flea infestations on dogs; Onsior, a non-steroidal short-term pain reliever for cats administered orally or by injection; Interceptor Plus, a canine heartworm drug that fights tapeworms in addition to hookworms, roundworms, and whipworms; and Osurnia, a gel formulation treatment for canine ear canal infection or inflammation. In January 2015, the company completed its acquisition of Novartis Animal Health (Novartis AH). Acquired Novartis AH products include Denagard, an antibiotic for the control and treatment of respiratory and enteric diseases in swine and poultry; Milbemax, an intestinal wormer which, if given monthly, also offers prevention against heartworm; Sentinel (outside the U.S.), a monthly tablet for the prevention of flea populations, the concurrent prevention of heartworm disease and the treatment of roundworms, hookworms, and whipworms in dogs; Atopica, for the treatment of chronic manifestations of atopic dermatitis in dogs and for the symptomatic treatment of chronic allergic dermatiti
eli lilly & co (LLY:Frankfurt)
Lilly Corporate Center
Indianapolis, IN 46285
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for LLY.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact ELI LILLY & CO, please visit www.lilly.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.